SLC16A1 and colorectal cancer: OSI, an irreversible EGFR/HER2 inhibitor, can upregulate the expression of monocarboxylate transporter 1 (MCT1) and then activate LKB1/AMPK signaling, leading to autophagy induction in colorectal cancer cells [21,22].